Showing results (1-10 of 4,339) with videos related to

Sort By:
Pageof 434
Cardiovascular Diabetology|April 8, 2021
Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patientsBoyang Xiang, Xiaoya Zhao, Xiang Zhou
Frontiers in Cardiovascular Medicine|January 31, 2022
Comparative Efficacy of Medical Treatments for Chronic Heart Failure: A Network Meta-AnalysisBoyang Xiang, Zongliang Yu, Xiang Zhou
Hypertension (Dallas, Tex. : 1979)|September 5, 2023
Association of Device-Measured Physical Activity With Cardiovascular Outcomes in Individuals With HypertensionBoyang Xiang, Yujia Zhou, Xiaoguang Wu, et al.
JAMA Network Open|September 20, 2022
Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysisBoyang Xiang, Ruiqi Zhang, Xiaoguang Wu, et al.
Research (Washington, D.C.)|August 11, 2025
Extrachromosomal Circular DNA MIRECD Enhances Necroptosis and Predicts Prognosis of Myocardial InfarctionYiheng Zhao, Yujia Zhou, Shuchen Zhang, et al.
Ebiomedicine|January 6, 2026
Nanotechnology for atherosclerotic plaque stabilisation: bridging innovation and clinical practiceYuxin Ren, Yujia Zhou, Boyang Xiang, et al.
Medcomm|May 19, 2025
Application of 68Ga- and 177Lu-Labeled FAP Inhibitor in Evaluation and Treatment of Cardiac Fibrosis After Myocardial InfarctionYiheng Zhao, Xiangyu Su, Boyang Xiang, et al.
Postgraduate Medical Journal|March 24, 2024
Is coffee, tea, and red wine consumption beneficial for individuals with hypertension?Shuchen Zhang, Boyang Xiang, Xiangyu Su, et al.
JACC. Advances|February 21, 2025
Unsupervised Learning-Derived Complex Metabolic Signatures Refine Cardiometabolic RiskYujia Zhou, Boyang Xiang, Xiaoqin Yang, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 3, 2026
METTL3-mediated N6-methyladenosine modification of Dnajb1 modulates cardiomyocyte ferroptosis during myocardial infarctionShuchen Zhang, Boyang Xiang, Yiheng Zhao, et al.
Pageof 434